NDAQ:VKTX) Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-CN) from The Globe and Mail including charting and trades.

Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...

Recent reports claim that cannabis can facilitate exercise by increasing motivation, performance and pleasure. Using cannabis ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Myristamide enhances cognitive function and BDNF in mice, indicating Camembert cheese's potential in combating cognitive ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.